Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ ABBV-303

Dragonfly Therapeutics, Inc. Massachusetts Illinois

(ClinicalTrials.gov Identifier: NCT06158958).

About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing novel therapies that harness the body's immune system to bring breakthrough treatments to patients. In addition to a set of advanced programs in the clinic, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platforms that are progressing toward the clinic, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.

For more information visit:
www.dragonflytx.com
https://www.linkedin.com/company/dragonfly-therapeutics-inc./
https://twitter.com/dragonflytx

DRAGONFLY MEDIA CONTACT:
Anne E. Deconinck | [e-mail]

Logo - https://mma.prnewswire.com/media/390962/Dragonfly_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/dragonfly-has-received-milestone-payment-following-dosing-of-first-patient-in-abbvie-phase-1-clinical-trial-evaluating-df4101abbv-303-302078944.html